Patents Assigned to Flexopharm Brain GMBH & Co. KG
  • Patent number: 11865091
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 9, 2024
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Patent number: 11602510
    Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 14, 2023
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventor: Aiden Haghikia
  • Patent number: 11471432
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: October 18, 2022
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Publication number: 20200323802
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
  • Publication number: 20200289442
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 17, 2020
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ralf Linker
  • Patent number: 10695305
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 30, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & CO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Publication number: 20200030267
    Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.
    Type: Application
    Filed: March 9, 2018
    Publication date: January 30, 2020
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventor: Aiden Haghikia
  • Publication number: 20180303778
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Application
    Filed: July 8, 2016
    Publication date: October 25, 2018
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
  • Publication number: 20170231933
    Abstract: The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing C3-C8 carboxylic acids, their physiologically tolerable salts and/or esters with C1-C8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.
    Type: Application
    Filed: October 19, 2015
    Publication date: August 17, 2017
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ralf Linker